Ozempic for Insulin Resistance: Evidence, Eligibility

Ozempic is not FDA approved for insulin resistance. It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.

Active ingredient: semaglutide
How it is taken: weekly injection
Approved for: Type 2 diabetes, heart risk and kidney disease in type 2 diabetes
Best result (STEP 1): 14.9% weight loss

Ozempic in brief

How long it remains in your body

Its half-life is about 1 week: by 7 d, half is gone, and about 3% remains after five half-lives (35 d).

Weight loss in its main trial

SUSTAIN 1 studied type 2 diabetes over 30 weeks: weight loss was 4.7 kg, compared with 1.2 kg on placebo.

Costs over time

Monthly prices in US dollars include the list price and self-pay offers, with each figure taken from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies for it?

Ozempic: who can qualify
Who sets the rule	Who qualifies for it?
FDA label	When used with diet and exercise, it helps adults with type 2 diabetes lower their blood sugar.
FDA label	Adults with type 2 diabetes and heart disease face a lower risk of heart attack, stroke, or heart-related death when they take it.
FDA label	Among adults who have type 2 diabetes plus chronic kidney disease, it reduces the chance of kidney disease worsening, kidney failure, and heart-related death.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	first comes a diet and activity program lasting 6 months

Information comes from FDA label on DailyMed, aetna.com.

Trial results for insulin resistance

No trial enrolled only people with insulin resistance. The adults studied had obesity or overweight, and none had diabetes.

Trials of the same ingredient (semaglutide)
Trial	Medicine	Who took part	Length	People	Main result	Comparison
STEP 1	Wegovy	Adults with obesity or overweight, without diabetes	68 weeks	1,961	14.9% weight loss	2.4% on placebo
OASIS 4	Wegovy	Adults with obesity or overweight, without diabetes	64 weeks	307	13.6% weight loss	2.4% on placebo

Trial data source: STEP 1 (FDA label (DailyMed)).

Insulin resistance: what changes?

Ozempic: label details for insulin resistance
What changes	What the label says
Low Blood Sugar When You Also Use Insulin Secretagogues or Insulin	Taking it with insulin or a sulfonylurea makes low blood sugar more likely, and you may need lower doses of those medicines.
Taken with insulin or sulfonylureas	Taking it with insulin, or with a sulfonylurea, for example glipizide or glimepiride, makes low blood sugar more likely. Your doctor may reduce those doses.

Source: FDA label on DailyMed.

Label warnings: FDA label (DailyMed).

What insulin resistance coverage looks like

A GLP-1 used only for weight loss is not covered by Medicare Part D.

In states where Medicaid covers weight-loss GLP-1s, you usually need prior authorization.

Sources: humana.com, KFF.

More options for insulin resistance

GLP-1 medicines and insulin resistance
Medicine	For insulin resistance	How it is taken	Trial result
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed